Home
-
A Global View: Bio/Pharma Mfg Investments
The wave of US-based manufacturing investments has garnered the headlines, but what are key ex-US capital projects by pharma companies? DCAT Value Chain Insights provides a global roundup.
-
Next Rx Drugs Selected for US Price Negotiations
The US government released this week the next 15 Rx drugs subject to price negotiations under the Inflation Reduction Act, the landmark legislation that put into place drug pricing reforms…
-
Industry Roundtable: Small-Molecule APIs: What’s in Store for 2026?
What are the pressing issues shaping the market for fine chemicals and pharma ingredients in 2026—the challenges and the opportunities? Senior executives from CDMOs share their perspectives.
DCAT MEMBER COMPANY COMMUNITY
-
New DCAT Member Company Alert
Welcome to the newest Member Companies in the Drug, Chemical & Associated Technologies Association (DCAT). DCAT is pleased to welcome the following companies to the DCAT Member Community. To view…
-
ESG Update: DCAT Member Companies in the Community
The latest ESG (environmental, social and governance)news from DCAT Member Companies on how they are making an impact globally and in their local communities. Have a ESG news announcement to share for…
-
People on the Move
Here are the latest moves and promotions of employees from the DCAT Member Company community. To submit a request to be included in People on the Move, click here. From the…
-
New Episode: Production to Prescription Podcast: 2025: The Bio/Pharma Industry’s Year in Review
Without question, evolving US tariff and trade policy was the story of the year in 2025, and how such policy will be implemented looms large. At the same time, the…
